应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01952 云顶新耀-B
交易中 07-29 09:36:20
18.980
+0.200
+1.06%
最高
18.980
最低
18.760
成交量
1.60万
今开
18.880
昨收
18.780
日振幅
1.17%
总市值
61.72亿
流通市值
61.72亿
总股本
3.25亿
成交额
30.19万
换手率
0.00%
流通股本
3.25亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
强化肾病和自免疫疾病领域领先优势 云顶新耀-B(01952)同类首创药物泽托佐米治疗狼疮性肾炎的临床试验完成中国首例患者给药
智通财经网 · 07-22
强化肾病和自免疫疾病领域领先优势 云顶新耀-B(01952)同类首创药物泽托佐米治疗狼疮性肾炎的临床试验完成中国首例患者给药
云顶新耀-B:午后涨 2.96% 关注耐赋康
和讯网 · 07-22
云顶新耀-B:午后涨 2.96% 关注耐赋康
云顶新耀-B现涨逾3% 耐赋康补充申请获国家药监局正式受理
新浪港股 · 07-22
云顶新耀-B现涨逾3% 耐赋康补充申请获国家药监局正式受理
港股异动 | 云顶新耀-B(01952)涨超4% 耐赋康补充申请获国家药监局正式受理 IgA肾病潜在市场空间较高
智通财经 · 07-22
港股异动 | 云顶新耀-B(01952)涨超4% 耐赋康补充申请获国家药监局正式受理 IgA肾病潜在市场空间较高
云顶新耀-B(01952)IgA肾病药物耐赋康®补充申请获NMPA正式受理 获批后治疗无基线蛋白尿水平限制
智通财经 · 07-18
云顶新耀-B(01952)IgA肾病药物耐赋康®补充申请获NMPA正式受理 获批后治疗无基线蛋白尿水平限制
云顶新耀-B07月17日主力资金流出28万元 连续3日减仓
自选股智能写手 · 07-17
云顶新耀-B07月17日主力资金流出28万元 连续3日减仓
云顶新耀-B07月08日主力资金流入12万元 连续5日加仓
自选股智能写手 · 07-08
云顶新耀-B07月08日主力资金流入12万元 连续5日加仓
云顶新耀-B(01952)下跌5.05%,报18.42元/股
金融界 · 07-08
云顶新耀-B(01952)下跌5.05%,报18.42元/股
云顶新耀-B(01952)股价下跌5.052%,现价港币$18.42
阿斯达克财经 · 07-08
云顶新耀-B(01952)股价下跌5.052%,现价港币$18.42
云顶新耀-B07月04日主力资金流入138万元 连续3日加仓
自选股智能写手 · 07-04
云顶新耀-B07月04日主力资金流入138万元 连续3日加仓
云顶新耀-B(01952)下跌5.01%,报18.6元/股
金融界 · 07-02
云顶新耀-B(01952)下跌5.01%,报18.6元/股
云顶新耀-B(01952)股价下跌5.005%,现价港币$18.6
阿斯达克财经 · 07-02
云顶新耀-B(01952)股价下跌5.005%,现价港币$18.6
创新药板块催化频出,港股创新药ETF(159567)跟踪指数走势较强,云顶新耀-B、来凯医药-B、翰森制药领涨。
有连云 · 06-25
创新药板块催化频出,港股创新药ETF(159567)跟踪指数走势较强,云顶新耀-B、来凯医药-B、翰森制药领涨。
云顶新耀-B午后涨超5% 长城证券给予买进的初始评级
新浪港股 · 06-25
云顶新耀-B午后涨超5% 长城证券给予买进的初始评级
港股异动 | 云顶新耀-B(01952)涨超5% IgA肾病潜在市场空间较高 机构看好公司产品端销售收入
智通财经 · 06-25
港股异动 | 云顶新耀-B(01952)涨超5% IgA肾病潜在市场空间较高 机构看好公司产品端销售收入
创新药有望加速进院,港股创新药ETF(159567)跟踪指数大幅上涨,复星医药、云顶新耀-B、翰森制药领涨。
有连云 · 06-25
创新药有望加速进院,港股创新药ETF(159567)跟踪指数大幅上涨,复星医药、云顶新耀-B、翰森制药领涨。
云顶新耀-B(01952)上涨5.21%,报21.0元/股
金融界 · 06-25
云顶新耀-B(01952)上涨5.21%,报21.0元/股
云顶新耀-B(01952)股价上升5.21%,现价港币$21.0
阿斯达克财经 · 06-25
云顶新耀-B(01952)股价上升5.21%,现价港币$21.0
医药“科特估”推动估值重塑,港股创新药ETF(159567)跟踪指数大幅上涨,云顶新耀-B、中国生物制药、康诺亚-B领涨。
有连云 · 06-19
医药“科特估”推动估值重塑,港股创新药ETF(159567)跟踪指数大幅上涨,云顶新耀-B、中国生物制药、康诺亚-B领涨。
云顶新耀-B(01952)下跌5.18%,报21.05元/股
金融界 · 06-06
云顶新耀-B(01952)下跌5.18%,报21.05元/股
暂无数据
公司概况
公司名称:
云顶新耀-B
所属市场:
SEHK
上市日期:
--
主营业务:
云顶新耀有限公司是一家主要从事疗法的特许、临床开发及商业化业务,以解决尚未满足的医疗需求。该公司一直专注于创新候选药物的研发。该公司已开发极具前景的临床阶段候选药物产品组合,覆盖肿瘤、免疫学、心肾疾病及感染性疾病。该公司主要在大中华及亚太区其他新兴市场提供产品与服务。
发行价格:
--
{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀-B","latestPrice":18.98,"timestamp":1722216836610,"preClose":18.78,"halted":0,"volume":16000,"delay":0,"floatShares":325164793,"shares":325164793,"eps":-2.8991375,"marketStatus":"交易中","marketStatusCode":2,"change":0.2,"latestTime":"07-29 09:36:20","open":18.88,"high":18.98,"low":18.76,"amount":301940,"amplitude":0.011715,"askPrice":19.04,"askSize":6000,"bidPrice":18.94,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-2.901906103485694,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1722225600000},"adr":0,"listingDate":1602172800000,"adjPreClose":18.78,"openAndCloseTimeList":[[1722216600000,1722225600000],[1722229200000,1722240000000]],"volumeRatio":0.900076,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952/tweets","defaultTab":"tweets","newsList":[{"id":"2453735655","title":"强化肾病和自免疫疾病领域领先优势 云顶新耀-B(01952)同类首创药物泽托佐米治疗狼疮性肾炎的临床试验完成中国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2453735655","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453735655?lang=zh_cn&edition=full","pubTime":"2024-07-22 13:35","pubTimestamp":1721626553,"startTime":"0","endTime":"0","summary":"7月22日,港股上市创新药企云顶新耀-B(01952)宣布,其同类首创药物泽托佐米(zetomipzomib)治疗活动性狼疮性肾炎(LN)的全球2b期PALIZADE试验已完成中国首例患者给药。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20240722/20240722133623_72715.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240722/20240722133623_72715.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01952","BK1576","BK1141","03347","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2453731516","title":"云顶新耀-B:午后涨 2.96% 关注耐赋康","url":"https://stock-news.laohu8.com/highlight/detail?id=2453731516","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453731516?lang=zh_cn&edition=full","pubTime":"2024-07-22 13:33","pubTimestamp":1721626425,"startTime":"0","endTime":"0","summary":"【云顶新耀-B午后上涨 2.96%,现报 20.20 港元,成交额 2025.15 万港元。】云顶新耀近日称,国家药监局已正式受理公司递交的耐赋康?最终临床试验阶段完整数据的补充申请。获批后,耐赋康?将成国内首个且唯一获国家药监局完全批准的 IgA 肾病对因治疗药物。中金此前表示,IgA 肾病潜在市场空间较高,但产品收入增长需积极商业化策略配合,建议关注耐赋康 24 年收入放量趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072214332395e750f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072214332395e750f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01952","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2453733530","title":"云顶新耀-B现涨逾3% 耐赋康补充申请获国家药监局正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2453733530","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453733530?lang=zh_cn&edition=full","pubTime":"2024-07-22 13:11","pubTimestamp":1721625073,"startTime":"0","endTime":"0","summary":"云顶新耀-B(01952)午后上涨2.96%,现报20.20港元,成交额2025.15万港元。\n 云顶新耀近日宣布,国家药监局已正式受理公司递交的耐赋康®(NEFECON®)最终临床试验阶段完整数据的补充申请。该补充申请获批后,耐赋康®将成为国内首个且唯一获得国家药监局完全批准的IgA肾病对因治疗药物。\n 中金此前指,IgA肾病潜在市场空间较高,但产品收入的增长需要积极的商业化策略配合,建议关注耐赋康24年收入放量趋势。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-22/doc-inceytkc4647862.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-22/doc-inceytkc4647862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["01952","BK1583","BK1161","BK1574"],"gpt_icon":0},{"id":"2453894057","title":"港股异动 | 云顶新耀-B(01952)涨超4% 耐赋康补充申请获国家药监局正式受理 IgA肾病潜在市场空间较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2453894057","media":"智通财经","labels":["Product Release","Policy And Regulatory"],"top":-1,"share":"https://www.laohu8.com/m/news/2453894057?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:45","pubTimestamp":1721616348,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,云顶新耀-B涨超4%,截至发稿,涨4.23%,报20.45港元,成交额1578.81万港元。消息面上,云顶新耀近日宣布,国家药监局已正式受理公司递交的耐赋康最终临床试验阶段完整数据的补充申请。该补充申请获批后,耐赋康将成为国内首个且唯一获得国家药监局完全批准的IgA肾病对因治疗药物。中金此前指,IgA肾病潜在市场空间较高,但产品收入的增长需要积极的商业化策略配合,建议关注耐赋康24年收入放量趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","HSTECH","BK1161","HSCEI","01952","BK1574","YANG"],"gpt_icon":1},{"id":"2452125998","title":"云顶新耀-B(01952)IgA肾病药物耐赋康®补充申请获NMPA正式受理 获批后治疗无基线蛋白尿水平限制","url":"https://stock-news.laohu8.com/highlight/detail?id=2452125998","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452125998?lang=zh_cn&edition=full","pubTime":"2024-07-18 12:34","pubTimestamp":1721277242,"startTime":"0","endTime":"0","summary":"对此,云顶新耀首席执行官罗永庆表示,耐赋康完全批准的补充申请获得NMPA的正式受理,为更多IgA肾病患者带来了新的希望。完全获批后治疗将无基线蛋白尿水平限制,中国人群中延缓肾功能衰退达66%资料显示,该补充申请是基于NefIgArd III期临床研究的完整数据。值得注意的是,耐赋康也是目前唯一一个获得FDA完全批准用于治疗有进展风险的IgA肾病的药物,并且无基线蛋白尿水平限制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2452187939","title":"云顶新耀-B07月17日主力资金流出28万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2452187939","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452187939?lang=zh_cn&edition=full","pubTime":"2024-07-17 16:15","pubTimestamp":1721204154,"startTime":"0","endTime":"0","summary":"07月17日, 云顶新耀-B股价涨1.70%,报收20.30元,成交金额2124万元,换手率0.32%,振幅3.96%,量比0.81。云顶新耀-B今日主力资金净流出28万元,连续3日净流出,上一交易日主力净流出88万元,今日环比减少68.18%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为50.00%,平均跌幅为3.61%。该股近5个交易日上涨7.98%,主力资金累计净流入22万元;近20日主力资金累计净流入638万元,其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071716161595cd6ba7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071716161595cd6ba7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","01952","BK1583"],"gpt_icon":0},{"id":"2449256687","title":"云顶新耀-B07月08日主力资金流入12万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2449256687","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449256687?lang=zh_cn&edition=full","pubTime":"2024-07-08 16:15","pubTimestamp":1720426533,"startTime":"0","endTime":"0","summary":"07月08日, 云顶新耀-B股价跌5.36%,报收18.36元,成交金额3016万元,换手率0.49%,振幅8.76%,量比0.85。云顶新耀-B今日主力资金净流入12万元,连续5日净流入,上一交易日主力净流入63万元,今日环比减少80.95%。近一年数据显示,该股主力连续5日净流入后,次日上涨概率为50.00%,平均涨幅为10.71%。该股近5个交易日下跌5.92%,主力资金累计净流入541万元;近20日主力资金累计净流入649万元,其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081615529f1d5ea9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407081615529f1d5ea9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01952","BK1583","BK1161"],"gpt_icon":0},{"id":"2449749921","title":"云顶新耀-B(01952)下跌5.05%,报18.42元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449749921","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449749921?lang=zh_cn&edition=full","pubTime":"2024-07-08 14:15","pubTimestamp":1720419333,"startTime":"0","endTime":"0","summary":"7月8日,云顶新耀-B(01952)盘中下跌5.05%,截至14:15,报18.42元/股,成交2037.19万元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司,主要业务是在全球范围内引进专利许可,开发和商业化创新性疗法,以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来,公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物,以满足尚未满足的医疗需求,服务于大规模的潜在患者人群。截至2023年年报,云顶新耀-B营业总收入1.26亿元、净利润-8.44亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/08141541427807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2449492577","title":"云顶新耀-B(01952)股价下跌5.052%,现价港币$18.42","url":"https://stock-news.laohu8.com/highlight/detail?id=2449492577","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449492577?lang=zh_cn&edition=full","pubTime":"2024-07-08 14:15","pubTimestamp":1720419300,"startTime":"0","endTime":"0","summary":"[下跌股]云顶新耀-B(01952) 股价在下午02:15比前收市价下跌5.052%,现股价为港币$18.42。至目前为止,今日最高价为$19.98,而最低价为$18.42。总成交量为107.55万股,总成交金额为港币$2.035千万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407082417/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01952","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2448441435","title":"云顶新耀-B07月04日主力资金流入138万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2448441435","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448441435?lang=zh_cn&edition=full","pubTime":"2024-07-04 16:15","pubTimestamp":1720080921,"startTime":"0","endTime":"0","summary":"07月04日, 云顶新耀-B股价跌0.52%,报收19.16元,成交金额3111万元,换手率0.50%,振幅4.26%,量比1.00。云顶新耀-B今日主力资金净流入138万元,连续3日净流入,上一交易日主力净流入259万元,今日环比减少46.72%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为81.25%,平均涨幅为3.21%。该股近5个交易日下跌8.07%,主力资金累计净流入310万元;近20日主力资金累计净流入21万元,其中净流入天数为9日。该股主力净额占比0.02%,港股市场排名140/2644。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041615359573d40f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041615359573d40f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1574","01952"],"gpt_icon":0},{"id":"2448900704","title":"云顶新耀-B(01952)下跌5.01%,报18.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448900704","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448900704?lang=zh_cn&edition=full","pubTime":"2024-07-02 14:24","pubTimestamp":1719901469,"startTime":"0","endTime":"0","summary":"7月2日,云顶新耀-B(01952)盘中下跌5.01%,截至14:24,报18.6元/股,成交4346.29万元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司,主要业务是在全球范围内引进专利许可,开发和商业化创新性疗法,以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来,公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物,以满足尚未满足的医疗需求,服务于大规模的潜在患者人群。截至2023年年报,云顶新耀-B营业总收入1.26亿元、净利润-8.44亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/02142441318451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","BK1161","BK1574","01952"],"gpt_icon":0},{"id":"2448188397","title":"云顶新耀-B(01952)股价下跌5.005%,现价港币$18.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2448188397","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448188397?lang=zh_cn&edition=full","pubTime":"2024-07-02 14:24","pubTimestamp":1719901440,"startTime":"0","endTime":"0","summary":"[下跌股]云顶新耀-B(01952) 股价在下午02:24比前收市价下跌5.005%,现股价为港币$18.6。至目前为止,今日最高价为$19.72,而最低价为$18.6。总成交量为228.005万股,总成交金额为港币$4.346千万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407021702/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1583","01952","BK1161"],"gpt_icon":0},{"id":"2446277861","title":"创新药板块催化频出,港股创新药ETF(159567)跟踪指数走势较强,云顶新耀-B、来凯医药-B、翰森制药领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446277861","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446277861?lang=zh_cn&edition=full","pubTime":"2024-06-25 14:21","pubTimestamp":1719296513,"startTime":"0","endTime":"0","summary":"2024年6月25日,港股创新药板块走势占优。盘面上,云顶新耀-B领涨,来凯医药-B、翰森制药跟涨,港股创新药ETF市场热度较高,过去5个交易日日均成交额6447万元。受益于个股业绩超预期海内外新药研发数据优秀等利好催化,减重药、艾滋病预防用药、脑机接口等热点主题表现相对活跃。当前医药生物板块整体表现持续低迷,市场情绪有待恢复,建议以中长线视角布局高景气细分领域投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062514215595d55b32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062514215595d55b32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","03692","BK1191","BK1583","BK1589","BK1574","01952","06978","02105"],"gpt_icon":0},{"id":"2446865362","title":"云顶新耀-B午后涨超5% 长城证券给予买进的初始评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2446865362","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446865362?lang=zh_cn&edition=full","pubTime":"2024-06-25 13:14","pubTimestamp":1719292440,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 云顶新耀-B(01952)午盘上涨5.21%,现报21港元,成交额3257.03万港元。\n 近日,长城证券给予云顶新耀买进的初始评级。 \n 中金此前指,IgA肾病潜在市场空间较高,但产品收入的增长需要积极的商业化策略配合,建议关注耐赋康24年收入放量趋势。由于23年产品端销售略超预期,该行对24/25年销售收入持相对乐观态度。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-25/doc-inazxpen1562758.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-25/doc-inazxpen1562758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01952","002939"],"gpt_icon":0},{"id":"2446857456","title":"港股异动 | 云顶新耀-B(01952)涨超5% IgA肾病潜在市场空间较高 机构看好公司产品端销售收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2446857456","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446857456?lang=zh_cn&edition=full","pubTime":"2024-06-25 11:55","pubTimestamp":1719287734,"startTime":"0","endTime":"0","summary":"消息面上,云顶新耀日前宣布,公司在第22届亚太肾脏病学大会与韩国肾脏病学会第44届年会上展示耐赋康治疗优势及探索IgA肾病治疗新策略。此外,云顶新耀上月宣布,耐赋康在中国首张处方成功落地,标志着这款全球首个IgA肾病对因治疗药物开始正式惠及中国内地的患者。中金此前指,IgA肾病潜在市场空间较高,但产品收入的增长需要积极的商业化策略配合,建议关注耐赋康24年收入放量趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HSCEI","07226","BK1574","YANG","HSTECH","BK1583","01952"],"gpt_icon":0},{"id":"2446550038","title":"创新药有望加速进院,港股创新药ETF(159567)跟踪指数大幅上涨,复星医药、云顶新耀-B、翰森制药领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446550038","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446550038?lang=zh_cn&edition=full","pubTime":"2024-06-25 10:22","pubTimestamp":1719282126,"startTime":"0","endTime":"0","summary":"2024年6月25日,港股创新药板块走势占优。此举标志着广东省在深化医疗保障制度改革、优化药品供应保障体系方面迈出了新的一步。此措施有助于进一步规范药品市场,保障公众用药需求,提高药品可及性、促进创新药行业健康发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062510221095d4b7e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062510221095d4b7e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1574","02196","BK1583","BK1161","BK1515","01952","BK1593","600196","BK1589","BK1191","03692"],"gpt_icon":0},{"id":"2446856892","title":"云顶新耀-B(01952)上涨5.21%,报21.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446856892","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446856892?lang=zh_cn&edition=full","pubTime":"2024-06-25 10:20","pubTimestamp":1719282027,"startTime":"0","endTime":"0","summary":"6月25日,云顶新耀-B(01952)盘中上涨5.21%,截至10:20,报21.0元/股,成交1580.88万元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司,主要业务是在全球范围内引进专利许可,开发和商业化创新性疗法,以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来,公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物,以满足尚未满足的医疗需求,服务于大规模的潜在患者人群。截至2023年年报,云顶新耀-B营业总收入1.26亿元、净利润-8.44亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/25102041176995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2446856747","title":"云顶新耀-B(01952)股价上升5.21%,现价港币$21.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2446856747","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446856747?lang=zh_cn&edition=full","pubTime":"2024-06-25 10:20","pubTimestamp":1719282000,"startTime":"0","endTime":"0","summary":"[上升股]云顶新耀-B(01952) 股价在上午10:20比前收市价上升5.21%,现股价为港币$21.0。至目前为止,今日最高价为$21.0,而最低价为$19.94。总成交量为75.6万股,总成交金额为港币$1.556千万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2406251234/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1583","BK1574","01952"],"gpt_icon":0},{"id":"2444417326","title":"医药“科特估”推动估值重塑,港股创新药ETF(159567)跟踪指数大幅上涨,云顶新耀-B、中国生物制药、康诺亚-B领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2444417326","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444417326?lang=zh_cn&edition=full","pubTime":"2024-06-19 13:21","pubTimestamp":1718774502,"startTime":"0","endTime":"0","summary":"2024年6月19日,港股创新药板块走势占优。盘面上,云顶新耀-B领涨,中国生物制药、康诺亚-B跟涨,港股创新药ETF市场热度较高,近5日日均成交额达到7469万元。方正证券表示,从医药细分领域来看,创新药高端医疗器械、医疗新科技等新质生产力均属于知识技术密集型产业,行业空间大,但估值相对于美股仍有较大提升空间。创新药BD浪潮持续走高,产品出海驱动行业高速发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406191321469f4d6fc9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406191321469f4d6fc9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1589","09939","BK1521","02162","BK1587","BK1574","01952","BK1161","BK1515","BK1583","01177"],"gpt_icon":0},{"id":"2441370407","title":"云顶新耀-B(01952)下跌5.18%,报21.05元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2441370407","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441370407?lang=zh_cn&edition=full","pubTime":"2024-06-06 10:16","pubTimestamp":1717640202,"startTime":"0","endTime":"0","summary":"6月6日,云顶新耀-B(01952)盘中下跌5.18%,截至10:16,报21.05元/股,成交3075.19万元。云顶新耀有限公司是一家专注于后期临床阶段的生物制药公司,主要业务是在全球范围内引进专利许可,开发和商业化创新性疗法,以满足大中华区和其他新兴亚太市场的医疗需求。自2017年成立以来,公司已在肿瘤、免疫、心肾疾病和感染性疾病领域打造了8种临床阶段候选药物,以满足尚未满足的医疗需求,服务于大规模的潜在患者人群。截至2023年年报,云顶新耀-B营业总收入1.26亿元、净利润-8.44亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/06101640923077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01952","BK1161","BK1583","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":-0.0428},{"period":"1month","weight":-0.1036},{"period":"3month","weight":-0.2381},{"period":"6month","weight":0.0906},{"period":"1year","weight":-0.169},{"period":"ytd","weight":-0.1014}],"compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0591},{"period":"3month","weight":-0.0357},{"period":"6month","weight":0.067},{"period":"1year","weight":-0.1333},{"period":"ytd","weight":-0.0015}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事疗法的特许、临床开发及商业化业务,以解决尚未满足的医疗需求。该公司一直专注于创新候选药物的研发。该公司已开发极具前景的临床阶段候选药物产品组合,覆盖肿瘤、免疫学、心肾疾病及感染性疾病。该公司主要在大中华及亚太区其他新兴市场提供产品与服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.043978},{"month":2,"riseRate":0.25,"avgChangeRate":0.025861},{"month":3,"riseRate":0.25,"avgChangeRate":-0.030941},{"month":4,"riseRate":0.25,"avgChangeRate":-0.098869},{"month":5,"riseRate":0.5,"avgChangeRate":-0.010924},{"month":6,"riseRate":0.75,"avgChangeRate":0.281644},{"month":7,"riseRate":0,"avgChangeRate":-0.160244},{"month":8,"riseRate":0,"avgChangeRate":-0.206077},{"month":9,"riseRate":0.666667,"avgChangeRate":0.011102},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.050127},{"month":11,"riseRate":0.5,"avgChangeRate":0.116383},{"month":12,"riseRate":0.75,"avgChangeRate":0.148847}],"exchange":"SEHK","name":"云顶新耀-B","nameEN":"EVEREST MED - B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀-B,01952,云顶新耀-B股票,云顶新耀-B股票老虎,云顶新耀-B股票老虎国际,云顶新耀-B行情,云顶新耀-B股票行情,云顶新耀-B股价,云顶新耀-B股市,云顶新耀-B股票价格,云顶新耀-B股票交易,云顶新耀-B股票购买,云顶新耀-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀-B(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀-B(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}